Skip to main content
. 2024 Jan 16;31(2):203–216. doi: 10.1038/s41418-024-01256-y

Fig. 1. ABLIM1 is aberrantly overexpressed in CRCs and augmented expression correlates with poor disease-free survival.

Fig. 1

A Representative ABLIM1 immunohistochemistry staining images of the CRC samples and adjacent normal counterparts in a tissue microarray. B Semiquantitative analysis results of immunohistochemistry staining images based on the H-score method. Data were shown as Mean ± SEM. ***P < 0.001 by paired student’s t-test. C Relative mRNA levels of ABLIM1 in 44 cases of freshly frozen CRC samples and their paired normal control mucosae. P = 0.007 determined by paired t-test. D ABLIM1 mRNA expressions in two datasets (GSE20916 and GSE5206) of the GEO database. Data were shown as Mean ± SEM. Unpaired student’s t test: *P < 0.05; **P < 0.01; ***P < 0.001. E Relative mRNA levels of ABLIM1 in a normal human colon epithelial cell line, HCoEpic, and 5 human CRC cell lines, including HCT116, RKO, SW480, SW620, and Lovo. N = 3 for each cell line. Kruskal–Wallis test. F ABLIM1 protein levels in HCoEpic and 5 human CRC cell lines were assayed by immunoblotting. Kaplan-Meier disease-free survival curves stratified by ABLIM1 expression levels using data downloaded from the CBioPortal database (G, TCGA PanCancer Atlas; H, TCGA Firehose Legacy). G P = 0.034, hazard ratio = 2.34 [1.04–5.33, 95% confidence interval (CI)]. H, P = 0.024, hazard ratio = 1.65 [1.08–2.50, 95% CI].